Utah Clinical Trials Report — April 2026

For Utah residents considering participation in clinical trials, April 2026 presents a critical window, especially for those looking to join studies that are nearing their enrollment deadlines. Across the state, 74 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 6 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Time is Running Out: Conditions with Trials Nearing Closure

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on specific types of cancer, heart conditions, and neurological disorders are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Acute lymphoblastic leukemia
• Heart failure
• Major depressive disorder
• Advanced breast cancer
• Stage IVB prostate cancer (AJCC V8)
• Advanced solid tumor
• Aortic regurgitation
• Alzheimer disease
• Advanced lung neuroendocrine tumor
• ALS - Amyotrophic lateral sclerosis

If you or a loved one are affected by these conditions, we encourage you to review the available trials and contact research sites quickly to determine eligibility.

New Horizons in Utah Research: April's Notable Studies

This month, Utah saw the opening of 14 new clinical trials, a decrease from the 20 trials that launched in March 2026. Despite this modest dip, the state continues to offer a diverse array of research opportunities, with several significant Phase 2 and 3 studies from major pharmaceutical companies and local institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges.

• Incyte Corporation is sponsoring NCT07522073, a Phase 3 study evaluating chemotherapy with or without INCB161734 for previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial seeks 588 participants to assess the efficacy and safety of this new approach.
• Eli Lilly and Company has launched multiple Phase 2 studies this month, including:
  • NCT07511816: A Phase 2 study evaluating LY4515100 in participants with acute pain following third molar removal. This trial aims to enroll 212 participants to assess the safety and efficacy of a single oral dose compared to placebo.
  • NCT07533006: A Phase 2 study of LY4005130 in adult participants with severe alopecia areata (hair loss), comparing the investigational drug to placebo in 60 participants.
  • NCT07533019: A Phase 2 study of LY4005130 in adult participants with non-segmental vitiligo, also comparing it to placebo in 60 participants.
• Jazz Pharmaceuticals is sponsoring NCT07533942, a Phase 2 study of JZP3507 (ONC206) in recurrent Grade 2 or 3 meningioma. This trial will recruit 30 participants who have failed prior therapy to evaluate the antitumor activity and safety of JZP3507.
• The University of Utah is leading NCT07515755, a study comparing supplemental oxygen and oxygen desaturations during colonoscopies. This research aims to track apnea and oxygen desaturation events among various methods of supplemental oxygen delivery in 280 colonoscopy patients.
• Mead Johnson Nutrition is sponsoring NCT07513506, an Extensively Hydrolyzed Formula Growth Monitoring Study. This study will compare an investigational infant formula against a currently marketed one, involving 214 participants to evaluate growth.

The types of interventions being studied are varied, with drug trials leading the way, accounting for 10 of the new trials this month. Other types of studies include device trials, dietary supplements, and radiation research.

Expanding Opportunities: Healthy Volunteers and Diverse Participation

For individuals without a specific medical condition, there are significant opportunities to contribute. 4 of the new trials this month are actively seeking healthy volunteers. Across Utah, a total of 95 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Participation in clinical trials is open to a wide range of individuals. Of the 14 new trials launched this month, 2 new trials include children, ensuring that younger populations have opportunities to contribute to medical science. Additionally, 10 new trials include older adults, making sure that senior populations are well-represented in new research initiatives.

Academic institutions continue to play a vital role in Utah's research ecosystem, with the University of Utah sponsoring 3 of the new trials, and Southern Utah University sponsoring one. Industry sponsors, including Eli Lilly and Company, Incyte Corporation, Exscientia AI Ltd., 4Life Research, LLC, Mead Johnson Nutrition, Sun Pharma Advanced Research Company Limited, and Jazz Pharmaceuticals, are also driving significant research efforts, accounting for 10 of the new studies this month.

Utah's Research Footprint: Where to Find Trials

Utah's clinical research landscape is robust, with 1,170 clinical trials currently recruiting across 43 cities and 520 research sites statewide. This broad distribution means that opportunities are often accessible beyond major metropolitan areas.

This month, the majority of new research initiatives are concentrated in the Salt Lake City metropolitan area. The cities with new trials opening include:

• Salt Lake City (7 new trials)
• South Jordan (3 new trials)
• Cedar (1 new trial)
• Sandy City (1 new trial)
• Syracuse (1 new trial)
• West Valley City (1 new trial)

New studies are exploring a range of conditions, from common ailments to more specialized areas. This month's new trials are targeting:

• Acute pain
• Airway obstruction
• Alopecia areata
• Apnea (central and obstructive)
• CML, refractory
• CML, relapsed
• Diffuse large B cell lymphoma
• Gastric cancer
• Growth
• Gut dysbiosis

As we move further into spring, the focus will likely remain on the ongoing enrollment in these significant Phase 2 and 3 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Utah.